 |
Advisory Panel on Research
May 21, 2008
Fairmont Washington Hotel
Agenda
8:30 a.m. - Introductions and Welcome
Larry J. Shapiro, M.D. -
APR Chair
David Korn, M.D. - AAMC Chief Scientific Officer, Biomedical and
Health Sciences Research
David Moore -
AAMC Sr. Associate Vice President, Office of Government Relations
David Korn, M.D.
Susan Ehringhaus, J.D. - AAMC Associate General Counsel for Regulatory
Affairs
The AAMC-AAU report released Feb. 28 calls on all medical schools
and major research universities to develop and implement institutional
financial conflict of interest (COI) policies in clinical research
within the next two years, and to refine standards for addressing
individual COIs. Further, the AAMC's Task Force on Conflicts
of Interest in Medical Education released its final report on
April 28. Dr. Korn and Ms. Ehringhaus will briefly present on
the deliberations and the major recommendations of the two separate
bodies. The APR is asked in particular to advise AAMC on next
steps to promote and implement the recommendations relating
to management of COI in Clinical Research. APR member Robert
Rich, M.D., was co-chair of the AAMC-AAU advisory committee,
and has been asked to open the panel's discussion of this topic.
David Davis, M.D. -
AAMC Vice President, Continuing Health Care Education and Improvement
The Panel last examined the topic of research on the "second
translational block" in Oct. 2006 in the context of the CTSA
awards. Dr. Davis will present on other aspects of this research
involving dissemination of knowledge and the role of physicians
as life-long learners. Dr. Davis will review the wide scope
of new initiatives within AAMC for use of continuing medical
education and other mechanisms to overcome the T2 Translational
block.
12 p.m. - Working Lunch
Deborah A. Zarin, M.D. -
NIH National Library of Medicine
Dr. Zarin, who presented to the panel in October, has been
asked to provide a progress report on the enhanced clinical
trials registration program and on the array of decisions that
the NLM has made in interpreting the FDAAA that will lead to
a forthcoming request for comment in the Federal Register. Many
decisions have focused on information required in reporting
results from clinical trials. [NB: the "open access" requirements
is also an issue at NLM that the panel will be interested in
revisiting.]
1:15 p.m. - Static Funding Environment
Dr. David Korn
The session will report on steps AAMC has taken following two
previous APR meetings on institutional and community response
to persisting flat NIH budgets and eroding purchasing power
of the Federal component for financing biomedical research.
Dr. Korn and staff will report on a recent presentation to the
Clinical Research Forum on recommendations following from the
APR, and a session of the recent GRAND (Research Deans) meeting
on institutional collaboration and on our recent recommendations
on the CTSA program.
2 p.m. - Concluding Discussions, Next Steps, and Future Topics
2:30 p.m. - Adjourn
|
|
|
